Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Extracorporeal shockwave therapy shows a number of treatment related chondroprotective effect in osteoarthritis of the knee in rats

  • Ching-Jen Wang1Email author,
  • Shan-Ling Hsu1,
  • Lin-Hsiu Weng1,
  • Yi-Chih Sun2 and
  • Feng-Sheng Wang2
BMC Musculoskeletal Disorders201314:44

DOI: 10.1186/1471-2474-14-44

Received: 3 January 2013

Accepted: 24 January 2013

Published: 28 January 2013

Abstract

Background

Extracorporeal shockwave therapy (ESWT) shows chondroprotective effect in osteoarthritis of the rat knees. However, the ideal number of ESWT is unknown. This study investigated the effects of different numbers of ESWT in osteoarthritis of the knee in rats.

Methods

Forty-five male Sprague-Dawley rats were divided into five groups. Group I underwent sham arthrotomy without anterior cruciate ligament transection (ACLT) or medial meniscectomy (MM) and received no ESWT. Group II underwent ACLT + MM and received no ESWT. Group III underwent ACLT + MM, and received ESWT once a week for one treatment. Group IV underwent ACLT + MM and received ESWT twice a week for 2 treatments. Group V underwent ACLT + MM and received ESWT three times a week for 3 treatments. Each treatment consisted of 800 impulses of shockwave at 14 Kv to the medial tibia condyle. The evaluations included radiographs of the knee, histomorphological examination and immunohistochemical analysis at 12 weeks.

Results

At 12 weeks, group II and V showed more radiographic arthritis than groups I, III and IV. On histomorphological examination, the Safranin O matrix staining in groups III and IV are significantly better than in groups II and V, and the Mankin scores in groups III and IV are less than groups II and V. Groups III and IV showed significant decreases of Mankin score and increase of Safranin O stain as compared to group I. Group V showed significant increases of Mankin score and a decrease of Safranin O stain as compared to group II. In articular cartilage, group II showed significant increase of MMP13 and decrease of collagen II as compared to group I. Groups III and IV showed significant decrease of MMP13 and increase of collagen II as compared to group I. Group V showed significant increase of MMP13 and decrease of collagen II as compared to group II. In subchondral bone, vWF, VEGF, BMP-2 and osteocalcin significantly decreased in groups II and V, but increased in groups III and IV relative to group I.

Conclusions

ESWT shows a number of treatment related chondroproctective effect in osteoarthritis of the knee in rats.

Keywords

Shockwave Number of treatment Chondroprotective Osteoarthritis Knee Rats

Background

Osteoarthritis (OA) of the knee has long being considered primarily a cartilage disease associated with cartilage loss and degradation. However, OA is usually accompanied by changes in the subchondral and periarticular bone such as sclerosis, bone cyst and osteophyte formation[1, 2]. The relationship between the subchondral bone changes and the initiation and progression of OA is still debated[35]. Emerging evidence shows that bone turnover increases in patients with osteoarthritis with subchondral bone loss in the early stage of OA and bone formation with osteophytes in the late stage[69]. Some authors proposed the potential role of subchondral bone changes in the initiation and progression of OA[10, 11]. It was suggested that increased subchondral bone stiffness reduces the ability of knee joint to dissipate the load and distribute the forces within the joint, and increases the force load on the overlying articular cartilage, which in turn accelerates the cartilage damage over time[6, 9]. Therefore, the functional integrity of the articular cartilage depends on the mechanical properties of the subchondral bone. For early osteoarthritis of the knee, the initial focus of treatment on articular cartilage or in subchondral bone remains controversial.

Extracorporeal shockwave therapy (ESWT) has shown effectiveness in many orthopedic disorders including soft tissue tendinopathy and non-union of long bone fractures[12, 13]. In addition, many studies reported positive effects of ESWT in various arthritic joints in animals[1418]. Other studies demonstrated that ESWT is chondroprotective in the initiation of OA changes of the knee[19], and induces regression or retardation of established OA changes of the knee in rats[20]. The ESWT dosages in the studies were based on the results of a pilot study that demonstrated 800 impulses of shockwave at 14 Kv applied to the subchondral bone of the medial tibia condyle showed better effects than 200, 400 and 1200 impulses in small animals. However, the optimal dosage and the ideal number of ESWT in osteoarthritis of the knee are unknown. Furthermore, many studies reported a dose-related effect of ESWT in bone[21], tendon[22], epigastric skin flap[23], tenocyte[24], and cells[25]. We hypothesized that the effect of ESWT in osteoarthritis of the knee may be related to the number of ESWT treatment. The purpose of this study was to investigate the effect of different numbers of ESWT treatment in osteoarthritis of the knee in rats.

Methods

The Institutional Review Board on animal experiment of Chang Gung Memorial Hospital, Taiwan approved this study. All studies were performed in accordance with the guidelines in the study and the care of animals in experiment.

Study design

This study was performed in 45 male Sprague-Dawley rats of 10-week old with body weight ranging from 275 mg to 315 mg. The anterior cruciate ligament transected (ACLT) and medial meniscectomized (MM) osteoarthritis knee model in rat was used[8]. The animals were divided into five groups with 9 rats in each group. Group I was the control and underwent sham arthrotomy of the knee without ACLT or MM and received no ESWT. Group II underwent ACLT and MM but no ESWT. Group III underwent ACLT + MM and received ESWT once a week for one treatment. Group IV underwent ACLT and MM and received ESWT twice a week for two treatments. Group V underwent ACLT and MM and received ESWT three times a week for three treatments. Radiographs of the knee in anteroposterior and lateral projections were performed at 0 and 12 weeks. Radiographs of the knee were obtained to assess bony appearance, focal osteoporosis, narrowing of joint space and spur formation. The animals were sacrificed at 12 weeks and the knee specimens were subjected to histomorphological examination and immunohistochemical analysis.

Anterior cruciate ligament transection and medial meniscectomy

The animals were sedated with intra-peritoneal phenobarbital injection (50 mg/Kg body weight). The left knee was prepared and draped in surgically sterile fashion. A straight anterior skin incision was made and the knee joint was opened through medial parapatellar arthrotomy. The anterior cruciate ligament was transected with a scalpel. Medial meniscectomy was performed by excising the entire medial meniscus. The knee was irrigated and the wound was closed in routine fashion. The animals were returned to the housing cages and were under the care of the veterinarian.

Shockwave application

ESWT was administered in groups III, IV and V in one week after knee surgery when the wound healed. The animals were sedated with intra-peritoneal phenobarbital injection (50 mg/Kg body weight). The source of shockwave is from an OssaTron orthotriptor (Sanuwave, Alpharetta, GA). The focus of shockwave treatment was the subchondral bone of the medial tibia condyle that was approximately 0.5 cm below the medial tibia plateau in anteroposterior view and 0.5 cm from the medial skin in lateral view (Figure1). The depth of treatment was confirmed with the laser indicator of the shockwave device. Ultrasound gel was applied to the skin in contact with the shockwave tube. Each treatment consisted of the application of 800 impulses of shockwave at 14 Kv (equivalent to 0.22 mJ/mm2). ESWT was performed once in group III, twice in group IV and three times in group V. After ESWT, the animals were returned to the housing cages and are under the care of the veterinarian.
https://static-content.springer.com/image/art%3A10.1186%2F1471-2474-14-44/MediaObjects/12891_2013_Article_1712_Fig1_HTML.jpg
Figure 1

A knee sketch shows the location of shockwave application in A-P (1-A) and lateral view (1-B).

Histomorphological examination

The animals were sacrificed at 12 weeks. The knee specimens including the articular cartilage and the subchondral bone of proximal tibia and distal femur were harvested. The specimens were decalcified and fixed in paraffin, and cut into 5-um thick sections using microderme and stained with heamtoxylin-eosin, Safranin-O, thionine and Alcian blue stains. The microscopic features of the articular cartilage included fissuring of the cartilage, chondrocyte proliferation, chondrocyte activity and chondrocyte apoptosis. The cartilage degradation was assessed by Mankin score that included cartilage structure, cartilage cells and tidemark integrity[26]. The matrix content was measured with Safranin O staining. The subchondral bone remodeling was evaluated with tissue distributions including cortical bone, cancellous bone and fibrous tissue.

Immunohistochemical analysis

The specimens were fixed in 4% PBS-buffered paraformaldehyde for 48 hours and decalcified in PBS-buffered 10% EDTA. Decalcified tissues were embedded in paraffin. The specimens were cut longitudinally into 5-um thick sections and transferred to poly-lysine-coated slides. Sections of the specimens were immunostained with specific reagents for vWF (von Willebrand Factor), VEGF (vessel endothelial growth factor), BMP-2 (bone morphogenic protein 2) and osteocalcin in subchondral bone, and MMP13 (matrix metalloproteinase 13) and collagen II in articular cartilage (Santa Cruz Biotechnology Inc, CA, USA). The immuno-reactivity in specimens was demonstrated using a horseradish peroxidase (HRP)-3′-, 3′-diaminobenzidine (DAB) cell and tissue staining kit (R & D Systems, Inc. Minneapolis, MN, USA). The immuno-activities were quantified from five areas in three sections of the same specimen using a Zeiss Axioskop 2 plus microscope (Carl Zeiss, Gottingen, Germany). All the images of each specimen were captured using a Cool CCD camera (SNAP-Pro c.f. Digital kit; Media Cybernetics, Sliver Spring, MD, USA). Images were analyzed using an Image-Pro® Plus image-analysis software (Media Cybernetics, Sliver Spring, MD, USA). The percentage of positive immuno-labeled cells over the total cells in each area was counted. A pathologist blinded to the nature of the study performed the measurements on all sections. The cartilage degradation was assessed with the measurements of MMP-13 and collagen II in the articular cartilage, and the subchondral bone remodeling by the measurements of vWF, VEGF, BMP-2 and osteocalcin.

Statistical analysis

The results of this study were expressed in median with ranges. Group I data were used as the baseline for statistical comparison with other groups. The P-values were obtained using ANOVA and post hoc test with Bonferoni correction among five groups, and Mann-Whitney “U” test between two groups. A statistical significance was set at p < 0.05.

Results

Radiographs of the knee showed no discernable difference among the 5 groups at 0 week. However, at 12 weeks, groups II and V showed more radiographic arthritis than groups I, III and IV (Figure2).
https://static-content.springer.com/image/art%3A10.1186%2F1471-2474-14-44/MediaObjects/12891_2013_Article_1712_Fig2_HTML.jpg
Figure 2

Radiographs of the knee at 12 weeks show more advanced osteoarthritis of the knee in groups II and V, and less arthritic changes in groups I, III and IV.

The results of Mankin score and Safranin O matrix staining are summarized in Table1 and Figure3. The microscopic features are shown in Figure4. The Safranin O matrix staining in group III and IV is significantly better than in groups II and V, and the Mankin scores in groups III and VI are less than groups II and V. The figures reflect a decreased Safranin O staining and an increased Mankin score associated with progression of osteoarthritis of the knee. The knees that were treated with one and two ESWT treatments showed significantly better Mankin score and Safranin O staining than knees treated with three ESWT treatments.
https://static-content.springer.com/image/art%3A10.1186%2F1471-2474-14-44/MediaObjects/12891_2013_Article_1712_Fig3_HTML.jpg
Figure 3

The results of Mankin score and Safranin O stain.

https://static-content.springer.com/image/art%3A10.1186%2F1471-2474-14-44/MediaObjects/12891_2013_Article_1712_Fig4_HTML.jpg
Figure 4

Microscopic features of the articular cartilage and subchondral bone in histomorphological examination.

Table 1

The results of Mankin score and Safranin O stain

Mankin score

    

Group I

Group II

Group III

Group IV

Group V

1 (1-1)

10 (9-12)

1 (0-2)

3 (2-4)

10 (8-11)

 

P1 = 0.0088

P2 = 1

P3 = 0.0742

P4 = 0.0102

  

P5 = 0.0017

P6 = 0.0038

P7 = 0.6213

   

P8 = 0.0705

P9 = 0.0022

    

P10 = 0.0052

Safranin O

    

Group I

Group II

Group III

Group IV

Group V

1 (1-1)

18.7 (16-20)

0.7 (0-1)

1.3 (1-2)

15 (12-17)

 

P1 = 0.0056

P2 = 0.4226

P3 = 0.4226

P4 = 0.0117

  

P5 = 0.0036

P6 = 0.0039

P7 = 0.1461

   

P8 = 0.2302

P9 = 0.0087

    

P10 = 0.0096

Group I: the control; Group II: ACLT + MM; Group III: ACLT + MM + ESWT 1×/week; Group IV: ACLT + MM + ESWT 2×/week; Group V: ACLT + MM + ESWT 3×/week.

ACLT: anterior cruciate ligament transection; MM: medial meniscectomy; ESWT: extracorporeal corporeal shockwave therapy.

P1: Group I vs Group II P2: Group I vs Group III P3: Group I vs Group IV.

P4: Group I vs Group V P5: Group II vs Group III P6: Group II vs Group IV.

P7: Group II vs Group V P8: Group III vs Group IV P9: Group III vs Group V.

P10: Group IV vs Group V.

The P values were obtained using ANOVA and post hoc test with Bonferoni correction among five groups, and the Mann-Whitney U test between two groups.

The results of MMP13 and collagen II of the articular cartilage are summarized in Table2 and Figure5. The microscopic features are shown in Figure6. Group II showed significant increase of MMP13 and decreases of collagen II as compared to group I indicating the progression of the knee arthritis. The changes of MMP-13 and collagen II in groups III and IV were comparable to group I, however, the changes in group V are closely similar to group II.
https://static-content.springer.com/image/art%3A10.1186%2F1471-2474-14-44/MediaObjects/12891_2013_Article_1712_Fig5_HTML.jpg
Figure 5

The results of MMP13 and collagen II in articular cartilage.

https://static-content.springer.com/image/art%3A10.1186%2F1471-2474-14-44/MediaObjects/12891_2013_Article_1712_Fig6_HTML.jpg
Figure 6

Microscopic features of MMP13 and collagen II in articular cartilage in immunohistochemical stains.

Table 2

The results of MMP13 and collagen II in articular cartilage

MMP13 (%)

    

Group I

Group II

Group III

Group IV

Group V

11.2 (9.4-12)

83.1 (79.5-89.3)

9.4 (7.8-11.3)

22.9 (11.8-27.3)

89.1 (88.5-92.4)

 

P1 = 0.0008

P2 = 0.3467

P3 = 0.1643

P4 < 0.0001

  

P5 = 0.0005

P6 = 0.0008

P7 = 0.1578

   

P8 = 0.1307

P9 < 0.0001

    

P10 = 0.0027

Collagen II (%)

    

Group I

Group II

Group III

Group IV

Group V

83.7 (80.4-87.5)

10.4 (7.6-11.7)

76 (73.7-82.1)

77.5 (76-83.7)

12.4 (11.5-14.5)

 

P1 < 0.0001

P2 = 0.1142

P3 = 0.2007

P4 = 0.0001

  

P5 = 0.0002

P6 = 0.0001

P7 = 0.1319

   

P8 = 0.6280

P9 = 0.0005

    

P10 = 0.0003

P1: Group I vs Group II P2: Group I vs Group III P3: Group I vs Group IV.

P4: Group I vs Group V P5: Group II vs Group III P6: Group II vs Group IV.

P7: Group II vs Group V P8: Group III vs Group IV P9: Group III vs Group V.

P10: Group IV vs Group V.

The P values were obtained using ANOVA and post hoc test with Bonferoni correction among five groups, and the Mann-Whitney U test between two groups.

The results of vWF, VEGF, BMP-2 and osteocalcin in subchondral bone are summarized in Table3 and Figure7. The microscopic features are shown in Figure8. Group II showed significant decreases of vWF, VEGF, BMP-2 and osteocalcin as compared to group I. Group III and IV showed significant increases of vWF, VEGF, BMP-2 and osteocalcin with the data comparable to group I. However, group V showed significant decreases of vWF, VEGF, BMP-2 and osteocalcin comparable to group II. It appears that one or two ESWT treatments showed beneficial effects, however, three ESWT treatments caused deteriorating changes.
https://static-content.springer.com/image/art%3A10.1186%2F1471-2474-14-44/MediaObjects/12891_2013_Article_1712_Fig7_HTML.jpg
Figure 7

The results of vWF, VEGF, BMP-2 and osteocalcin in subchondral bone.

https://static-content.springer.com/image/art%3A10.1186%2F1471-2474-14-44/MediaObjects/12891_2013_Article_1712_Fig8_HTML.jpg
Figure 8

Microscopic features of vWF, VEGF. BMP-2 and osteocalcin in subchondral bone in immunohistochemical stains.

Table 3

The results of vWF, VEGF, BMP-2 and osteocalcin in subchondral bone

vWF (%)

    

Group I

Group II

Group III

Group IV

Group V

81.9 (78.9-86.8)

16.2 (15.4-19.5)

84.8 (79.7-89.1)

73.8 (62.9-78.3)

17.6 (13.1-20.3)

 

P1 = 0.0001

P2 = 0.8696

P3 = 0.1253

P4 < 0.0001

  

P5 = 0.0012

P6 = 0.0044

P7 = 0.9899

   

P8 = 0.1156

P9 = 0.0004

    

P10 = 0.0022

VEGF (%)

    

Group I

Group II

Group III

Group IV

Group V

82.8 (79-84.6)

15.4 (11.2-19.5)

72.5 (68.6-80.4)

78.3 (73.8-83.5)

13.1 (11.3-17.6)

 

P1 = 0.0001

P2 = 0.1239

P3 = 0.3432

P4 < 0.0001

  

P5 = 0.0003

P6 = 0.0001

P7 = 0.6777

   

P8 = 0.3540

P9 = 0.0005

    

P10 = 0.0001

BMP2 (%)

    

Group I

Group II

Group III

Group IV

Group V

84.4 (77.1-91)

11.2 (9.4-15.4)

74.6 (73.1-89.1)

72.9 (68.3-73.8)

13.1 (12.4-14.6)

 

P1 = 0.0008

P2 = 0.4670

P3 = 0.0729

P4 = 0.0026

  

P5 = 0.0027

P6 < 0.0001

P7 = 0.5312

   

P8 = 0.2893

P9 = 0.0054

    

P10 = 0.0002

OCN (%)

    

Group I

Group II

Group III

Group IV

Group V

79.6 (69.6-82.2)

10.5 (9.4-11.2)

76.7 (76.1-87.8)

73.8 (62.9-77.3)

9.1 (8.5-12.4)

 

P1 = 0.0029

P2 = 0.6008

P3 = 0.3741

P4 = 0.0016

  

P5 = 0.0025

P6 = 0.0045

P7 = 0.8010

   

P8 = 0.2002

P9 = 0.0014

    

P10 = 0.0029

P1: Group I vs Group II P2: Group I vs Group III P3: Group I vs Group IV.

P4: Group I vs Group V P5: Group II vs Group III P6: Group II vs Group IV.

P7: Group II vs Group V P8: Group III vs Group IV P9: Group III vs Group V.

P10: Group IV vs Group V.

The P values were obtained using ANOVA and post hoc test with Bonferoni correction among five groups, and the Mann-Whitney U test between two groups.

Discussion

The results of the current study showed that ESWT protects the articular cartilage degradation and improves subchondral bone remodeling in the initiation of osteoarthritis of the knee in rats. The results are in agreement with prior studies that shockwave has chondroprotective effect in OA knee in rats[19, 20], The subchondral bone remodeling relies on the balance between bone formation by osteoblast and bone resorption by osteoclast, and is influenced by the subchondral bone mass and bone strength. The effects on articular cartilage were supported by the changes of Mankin score, Safranin O stain, MMP-13 and collagen II. MMP-13 is involved in cartilage turnover and cartilage pathophysiology associated with osteoarthritis. Collagen II is the base of articular cartilage and hyaline cartilage that form fibrillar network of collagen that allows cartilage to entrap the proteoglycan aggregate and provide tensile strength to the tissue. The effects of ESWT in subchondral bone remodeling were supported by the increased vascularization manifested by the changes of vWF, eNOS and VEGF, and osteogenesis manifested by the changes in BMP-2, alkaline phosphatase and osteocalcin. vWF is a large glycoprotein in plasma and endothelium and a positive vWF is indicative of new vessel formation. eNOS is an immune transmitter and vasodilator in tissue healing . VEGF is a protein that stimulates vasculogenesis and angiogenesis and an indication of increased vascular permeability and microvascular activities including the angiogenic growth of new vessels. BMP-2 is osteoinductive and induces osteoblast differentiation. Alkaline phosphatase is a hydrolase enzyme responsible for dephosphorylation. Osteocalcin is pre-osteoblastic and bone-building in nature.

The current study also demonstrated that ESWT has a number of treatment related effect in osteoarthritis of the knee. Many studies reported dose-dependent effects of ESWT in different tissues[2125]. ESWT showed a dose-related enhancement in bone mass and bone strength after fracture of the femur in rabbits[21]. Other study reported a dose-related effect of shockwaves on rabbit tendon Achilles[22]. In a murine skin flap model, ESWT between 500 and 2500 impulses showed a dose-dependent effect in epigastric flap survival[23]. ESWT also showed dose-dependent changes in cell viability, MMP 1, 2 and 3 and IL-6 on cultured tenocytes[24]. Another study stated that one of the most important aspects to be considered is not the total number of impulses used but the energy level of the shockwaves, thus confirming that ESWT has a dose-dependent effect on osteoblast cells[25]. An optimal ESWT dosage may result in beneficial effects, whereas, overdose of ESWT can cause deteriorating effect and damage to the subchondral bone and articular cartilage of the knee. The current study demonstrated that one or two ESWT treatments showed beneficial effect, however, three ESWT treatments caused deteriorating results. Additional studies including clinical trial are needed to validate the ideal numbers of ESWT for osteoarthritis of the knee in humans.

The exact mechanism of ESWT remains unknown. Recent studies showed that ESWT induces the ingrowth of neovascularization and up-regulation of angiogenic and osteogenic growth factors that leads to improvement in blood perfusion and tissue regeneration[27]. The innovative findings in this study may unveil a new concept in the management of osteoarthritis of the knee by shifting the initial treatment focus from the articular cartilage to the subchondral bone. Furthermore, ESWT has the potential used in the treatment of osteoarthritis of the knee.

There are limitations in this study. The data obtained from this study were based on experiments in small animals. The results may differ in larger animals or human subjects. The dose conversion (energy level and the total energy) from small animals to larger animals or human subjects must be validated with additional studies including clinical trial. This study demonstrated that the effect of ESWT is related to the number of treatment, but not necessarily the dosage in knee OA, and the optimal ESWT dosage and the ideal numbers of ESWT treatment remains unknown. Furthermore, different manufacture companies used different indices of shockwave parameters, and the dose conversion formula among the different devices are not readily available at the present time.

Conclusion

ESWT shows a number of treatment related chondroprotective effects and improves subchondral bone remodeling in the initiation of osteoarthritis of the knee in rats. Additional studies are needed to validate the optimal ESWT dosage and the number of treatment for osteoarthritis of the knee.

Declarations

Acknowledgement

Funds were received in total or partial support for the research or clinical study presented in this article. The funding sources were from Chang Gung Research Fund (CMRPG890681).

Authors’ Affiliations

(1)
Department of Orthopedic Surgery, Chang Gung University College of Medicine Kaohsiung Chang Gung Memorial Hospital
(2)
Department of Medical Research, Chang Gung University College of Medicine Kaohsiung Chang Gung Memorial Hospital

References

  1. Lane NE, Nevitt MC: Osteoarthritis, bone mass, and fractures: how are they related?. Arthritis Rheum. 2002, 46: 1-4. 10.1002/1529-0131(200201)46:1<1::AID-ART10068>3.0.CO;2-P.View ArticlePubMedGoogle Scholar
  2. Oettmeier R, Abendroth K: Osteoarthritis and bone: osteologic types of osteoarthritis of the hip. Skeletal Radiol. 1989, 18: 165-174. 10.1007/BF00360962.View ArticlePubMedGoogle Scholar
  3. Burr DM, Schaffler MB: The involvement of subchondral mineralized tissues in osteoarthrosis: quantitative microscopic evidence. Micros Res Tech. 1997, 37: 343-357. 10.1002/(SICI)1097-0029(19970515)37:4<343::AID-JEMT9>3.0.CO;2-L.View ArticleGoogle Scholar
  4. Burr DB: The importance of subchondral bone in osteoarthrosis. Curr Opin Rheumatol. 1998, 10: 256-262. 10.1097/00002281-199805000-00017.View ArticlePubMedGoogle Scholar
  5. Radin EL, Rose RM: Role of subchondral bone in the initiation and progression of cartilage damage. Clin Orthop. 1986, 213: 34-40.PubMedGoogle Scholar
  6. Dedrick DK, Goulet R, Huston L, Goldstein SA, Bole GG: Early bone changes in experimental osteoarthritis using microscopic computed tomography. J Rheumatol. 1991, 27 (Suppl): 44-45.Google Scholar
  7. Hayami T, Funaki H, Yaoeda K, Mitui K, Yamagiwa H, Tokunaga K, Hatano H, Kondo J, Hiraki Y, Yamamoto T, Duong le T, Endo N: Expression of the cartilage derived anti-angiogenic factor chondromodulin-I decreases in the early stage of experimental osteoarthritis. J Rheumatol. 2003, 30: 2207-2217.PubMedGoogle Scholar
  8. Hayami T, Pickarski M, Zhuo Y, Wesolowski GA, Rodan GA, le Duong T: Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. Bone. 2006, 38 (2): 234-243. 10.1016/j.bone.2005.08.007.View ArticlePubMedGoogle Scholar
  9. Ratcliffe A, Seibel MJ: Biochemical markers of osteoarthritis. Curr Opin Rheumatol. 1990, 277: 21352-21360.Google Scholar
  10. Muraoka T, Hagino H, Okano T, Enokida M, Teshima R: Role of subchondral bone in osteoarthritis development: a comparative study of two strains of guinea pigs with and without spontaneously occurring osteoarthritis. Arthritis Rheum. 2007, 56 (10): 3366-3374. 10.1002/art.22921.View ArticlePubMedGoogle Scholar
  11. Dieppe P: Subchondral bone should be the main target for the treatment of pain and disease progression in osteoarthritis. Osteoarthritis Cartilage. 1999, 7 (3): 325-326. 10.1053/joca.1998.0182.View ArticlePubMedGoogle Scholar
  12. Wang CJ: An overview of shock wave therapy in musculoskeletal disorders. Chang Gung Med J. 2003, 26: 220-232.PubMedGoogle Scholar
  13. Wang CJ: Extracorporeal shockwave therapy in musculoskeletal disorders. [Review] Journal of Orthopaedic Surgery & Research. 2012, 7: 11-10.1186/1749-799X-7-11.View ArticleGoogle Scholar
  14. Dahlberg J, Fitch G, Evans RB, McClure SR, Conzemius M: The evaluation of extracorporeal shockwave therapy in naturally occurring osteoarthritis of the stifle joint in dogs. Vet Comp Orthop Traumatol. 2005, 18 (3): 147-152.PubMedGoogle Scholar
  15. Frisbie DD, Kawcak CE, Mcllwraith CW: Evaluation of the effect of extracorporeal shock wave treatment on experimentally induced osteoarthritis in middle carpal joints of horses. Am J Veterinary Res. 2009, 70 (4): 449-454. 10.2460/ajvr.70.4.449.View ArticleGoogle Scholar
  16. Mueller M, Bockstahler B, Skalicky M, Mlacnik E, Lorinson D: Effects of radial shockwave therapy on the limb function of dogs with hip osteoarthritis. Vet Rec. 2007, 160 (22): 762-765. 10.1136/vr.160.22.762.View ArticlePubMedGoogle Scholar
  17. Ochiai N, Ohtori S, Sasho T, Nakagawa K, Takahashi K, Takahashi N, Murata R, Takahashi K, Moriya H, Wada Y, Saisu T: Extracorporeal shock wave therapy improves motor dysfunction and pain originating from knee osteoarthritis in rats. Arthritis & Cartilage. 2007, 15 (9): 1093-1096.View ArticleGoogle Scholar
  18. Revenaugh MS: Extracorporeal shock wave therapy for treatment of osteoarthritis in the horse: clinical application. Vet Clin North Am Equine Pract. 2005, 21 (3): 609-625. 10.1016/j.cveq.2005.09.001.View ArticlePubMedGoogle Scholar
  19. Wang CJ, Weng LH, Ko JY, Sun YC, Yang YJ, Wang FS: Extracorporeal shockwave therapy shows chondroprotective effects in osteoarthritic Rat knee. Arch Orthop Trauma Surg. 2011, 131: 1153-1158. 10.1007/s00402-011-1289-2.View ArticlePubMedGoogle Scholar
  20. Wang CJ, Weng LH, Ko JY, Wang JW, Chen JM, Sun YC, Yang YJ: Extracorporeal shockwave shows regression of osteoarthritis of the knee in rats. J Surg Res. 2011, 171: 601-608. 10.1016/j.jss.2010.06.042.View ArticlePubMedGoogle Scholar
  21. Wang CJ, Yang KD, Wang FS, Chen HS, Chen HH, Hsu CC: Shock wave therapy enhances bone mass and bone strength after fracture of the femur. A study in rabbits. Bone. 2004, 34: 225-230. 10.1016/j.bone.2003.08.005.View ArticlePubMedGoogle Scholar
  22. Rompe JD, Kirpatrick CJ, Kullmer K, Schneitalle M, Krischeck O: Dose-related effects of shockwaves on rabbit tendon Achilles. J Bone Joint Surg Br. 1998, 80: 546-552. 10.1302/0301-620X.80B3.8434.View ArticlePubMedGoogle Scholar
  23. Kamelger F, Oehlbauer M, Piza-Katzer H, Meirer R: Extracorporeal shock wave treatment in ischemic tissues: what is the appropriate number of shock wave impulses?. J Reconstructive Microsurgery. 2010, 26 (2): 117-121. 10.1055/s-0029-1243296.View ArticleGoogle Scholar
  24. Han SH, Lee JW, Guyton GP, Parks BG, Courneya JP, Schon LC: Effect of extracorporeal shock wave therapy on cultured tenocytes. Foot Ankle Int. 2009, 30 (2): 93-98. 10.3113/FAI.2009.0093.PubMedGoogle Scholar
  25. Martini L, Fini M, Giavaresi G, Torricelli P, DePretto M, Rimondini L, Giardino R: Primary osteoblasts response to shock wave therapy using different parameters. Artif Cells Blood Substit Immobil Biotechnol. 2003, 31 (4): 449-466. 10.1081/BIO-120025415.View ArticlePubMedGoogle Scholar
  26. Mankin HJ, Dorfman H, Lippiello L, Zarins A: Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips: II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am. 1971, 53: 523-537.PubMedGoogle Scholar
  27. Wang CJ, Wang FS, Yang KD, Huang CS, Hsu CC: Shock wave therapy induces neovascularization at the tendon-bone junction. A study in rabbits. J Orthop Res. 2003, 21: 984-989. 10.1016/S0736-0266(03)00104-9.View ArticlePubMedGoogle Scholar
  28. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2474/14/44/prepub

Copyright

© Wang et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.